News round-up by DDW’s Megan Thomas for 22-26 November
As the year draws to a close, looking both back and forward to identify and anticipate trends and market behaviour is important. This week, DDW’s Megan Thomas has rounded up five stories which identify interesting and impactful trends and analysis with may influence the future of drug discovery.
A group of researchers at Qatar Foundation and Hamad Medical Corporation has released a study that highlights a total of 60 disease-causing genetic variants linked with cancer, heart diseases, high cholesterol level and other diseases, with cancer-associated variants being the most frequent – which is consistent with the high prevalence of cancer in the Qatari population.
The global drug discovery informatics market size is expected to reach $5.62 billion by 2028 according to a new study by Polaris Market Research. The report gives insight into current market dynamics and provides analysis on future market growth.
CRB has released an industry report based on survey responses from more than 500 industry leaders and with unique analysis from CRB’s life sciences subject matter experts.
While trial activity has since recovered to pre-Covid-19 pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData.
The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GolbalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.